Transforming traumatic memories: The Reconsolidation of Traumatic Memories (RTM) protocol

The Research and Recognition Project (a 501(c)(3) organization)

Frank Bourke, CEO
Frank.Bourke@randrproject.com

Richard Gray, Research Director
Richard.Gray@randrproject.com
Reconsolidation of Traumatic Memories (RTM)

A novel, non-traumatizing, brief therapy for PTSD characterized by intrusive symptoms

**Novel:** anecdotal 25-year clinical history supported by recent RCTs and nearly 20 years of research on reconsolidation

**Non-traumatizing:** Client comfort and safety are crucial: Mean dropout rate is lower than 10%.

**Brief:** Typically completed in three 90 – minute sessions.

**Targeted:** Intrusive symptoms: nightmares, flashbacks, and sympathetic reactivity
Reconsolidation of Traumatic Memories (RTM)

• RTM has been tested in 5 RCTS using 160 service related men and women to obtain loss of diagnosis in more than 90 percent of those completing treatment.

• It has successfully treated complex traumas including combat trauma, sexual trauma, military sexual trauma, childhood sexual abuse, first responder trauma, and other issues.

• It has treated late onset and continuing PTSD symptoms from the Vietnam and Korean Wars, as well as more recent conflicts.
Reconsolidation

• A long-term memory is confronted with information that contradicts some essential element of the memory (but not the entire memory), or novel information (Prediction Error [PE]; Pedreira, et al. 2004)

• That memory becomes labilized--subject to change--for a period of about 1-6 hours (Nader, 2003; Nader, Schafe, & LeDoux, 2000; Monfils, Cowansage, Klann, & LeDoux, 2009),

• During that period, The memory’s importance can then be strengthened or weakened (salience), its emotional tone may be changed, or its content changed.
RTM: Hypothesis on How it works

• RTM restructures the visual representations of a trauma memory as a past, non-threatening memory, by changing elements of the memory.

• These changes include, from a dissociated perspective, the loss of color, the loss of depth cues, increased distance, as well as, visual and temporal distortions.

• RTM makes these format changes in a labilization window created by a very brief, non traumatizing exposure. In this dissociated window these format changes block normal reconsolidation of the trauma memory separating the traumatic memory from the traumatic feeling.

• Reconsolidation allows for fast and robust de-traumatization to the memory measured out to one year and surveyed out to 5 years.
What we do--in four steps

1. A brief exposure opens a window during which the memory becomes susceptible to change.

2. The client is guided through repeated versions of a dissociated, black & white, imaginal movie from the perspective of a dissociated watcher, watching themselves sitting in a movie theater as they watch the black and white movie of the traumatic event.

3. When comfortable, the client steps into the end of the event and re-experiences it as an associated, multi-sensory, reversed experience--in about two seconds.

4. The client finally creates an alternative version of the trauma event that is practiced until comfortable.

SUDs assessments serve as checks on client progress through the cycles of treatment.
Success Criteria

• Symptom scores drop below clinical and diagnostic cut-offs; most clients fail to endorse DSM criteria
• Flashbacks and nightmares relation to the events treated cease
• Event narrative fails to evoke negative sympathetic arousal
• The event is recalled easily with richer details
• The event is recalled like JUST another memory
• The event takes on different significance in the client’s life; it is spontaneously reappraised
• Family members report observed changes
• Previous Trauma Triggers no longer activate responses
• Results have stayed robust across one year follow-ups
RTM creates dramatic reductions in symptom severity

PSS-I scores for three studies at Intake, 2 weeks, 6 months and one year post

<table>
<thead>
<tr>
<th>Studies</th>
<th>Intake</th>
<th>2 Weeks</th>
<th>6 months</th>
<th>12 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tylee et al, 2017</td>
<td>39.78</td>
<td>7.82</td>
<td>3.4</td>
<td></td>
</tr>
<tr>
<td>Gray et al., 2017</td>
<td>38.5</td>
<td>15.7</td>
<td>17.6</td>
<td></td>
</tr>
<tr>
<td>Gray et al. SUBMITTEDs</td>
<td>41.1</td>
<td>8.4</td>
<td>8.2</td>
<td>7.7</td>
</tr>
</tbody>
</table>
Comparison of RTM with Mainline Military Treatments for PTSD (Percentages)

- **RTM FEMALE VETERANS** (N = 30)
- **RTM MALE VETERANS** (N = 30)
- **RTM MALE VETERANS** (N = 74)
- **PE, FOA ET AL., 2018** (N = 109)
- **MASSED PE, FOA ET AL., 2018** (N = 110)
- **PE, YEHUDA ET AL., 2014** (N = 37)
- **PE, SCHNURR ET AL., 2007** (N = 141)
- **CPT, MONSON ET AL., 2006** (N = 30)
- **CPT, FORBES ET AL., 2012** (N = 30)
- **GROUP CPT TELEMEDICINE MORLAND ET AL., 2014...**
  - **GROUP CPT MORLAND ET AL., 2014...**
  - **CPT, SURÍS ET AL., 2013** (N = 72)
  - **PCT, FOA ET AL., 2018** (N = 107)
  - **PCT, SURÍS ET AL., 2013** (N = 72)
  - **PCT, SCHNURR ET AL., 2007** (N = 143)

- **% Remission (PCL-M-RTM only)**
- **% remission (PSS-I)**
- **% dropouts**
RTM RESEARCH RESULTS:
Pilot Study (Gray & Bourke, 2015; NY $300,000 Grant).

• Thirty-person RCT with 26 treatment completers. Requiring a pre-existing Dx of PTSD and prior month flashback or nightmare for inclusion.

• Mean intake score: 61; mean post Tx PCL reduction: 44.7 ± 15.8 points; final mean PCL-M score of 28.8 ± 7.5 at 6 weeks or the last measure reported.

• 6 week Hedges’ g 2.9 (CI 99% [26.05, 33.71]).
RTM RESEARCH RESULTS:
First Replication Study *Tylee et al. (2017)*.

- 94% of 30 male veterans were **symptom free** at all follow-ups *to one year post*.

- **Mean reduction of 39.8 points** (*PCL-M*; cumulative intake mean = 66.5 ± 8.27) for all treatment completers, with a final mean *PCL-M* score of 26.8 ± 13.08 at 6 months. **Hedges’ g = 3.59** for all treatment completers at 6-months post (CI 99% [22.06, 33.54]).

- **Experimental comparison**: Waitlisted controls at week 6 vs RTM Group at two weeks post: **Hedges g = 3.663** (95% CI [6.013–1.314]).

- **Twelve-month mean PCL-M scores** for treatment completers, with 81.5% reporting, were **20.9 (± 4.2)**, a reduction of 46.5 points.
RTM RESEARCH RESULTS:

Second Replication Study. 30 Females (Gray et al. Submitted manuscript.) Waitlist RCT with ITT analysis.

• 96% of the 30 women were symptom and diagnosis free at all follow-ups to 1 year despite extensive histories of complex PTSD with MST, rapes, and repeated childhood traumas.

• Mean symptom score reduction of 43 points PCL-M and 34 points PSS-I. Two-week pooled results PSS-I Mean = 7.172 ± 9.289; PCL-M Mean = 26.993 ± 13.473) compared to baseline (PSS-I Mean = 41.1 ± 6.093; PCL-M Mean = 70.3 ± 7.831) were statistically significant (P<0.001). Scores for six weeks, six-months, and one-year did not change significantly from 2-week measures.

• Experimental comparison: Untreated waitlist participants at end of the period (PSS-I Mean = 38.6 ± 6.456; PCL-M Mean = 67.13 ± 8.46) vs treatment subjects two-weeks post (PSS-I Mean = 9.667 ± 11.703; PCL-M Mean = 25.43 ± 8.06), were significantly different in the expected direction (p < 0.001).

Effect size for experimental comparison: Hedges’ g (PSS-I g = 3.0; 95% CI [-0.4 to 6.4; PCL-M g = 3.4. 95% CI [-0.7 to 7.4].
RTM RESEARCH RESULTS:
Third Replication Study. (NY $800 K Grant); Gray, Budden-Potts, & Bourke (2017).

• 90% of the 64 male veterans completing treatment scored below diagnostic threshold on the PCL-M at two wks, 6 wks, and 6 months post treatment.

• **Primary measure:** PSS-I mean symptom score reductions of 23 points at 6 months. Mean PSS-I intake score was 38.5 ± 6.783. final mean scores at 6 months were 15.38 ± 15.23 (p < 0.001).

• **Experimental comparison:** Untreated waiting list controls compared to treatment group at equivalent time points, differed significantly (p. < 0.001) in the expected direction.
RTM RESEARCH RESULTS:

Investigation of RTM treatment with pre-post EEG Measures. (NM private funders). Submitted for publication.

- The lead author had previously identified an EEG footprint for PTSD as strong high beta activation in resting temporal lobe and dPFC.
- A group of 12 males and 15 females from a population of Veterans, Active military and first responders previously diagnosed with PTSD were compared to a previously collected sample of 30 Neurotypical adults.
- PTSD subjects with and without aberrant high Beta responding, responded well to RTM.
- Among those showing the PTSD signature, there were dramatic reductions in post treatment high-Beta response.
QEEG Results Pre- Post- RTM Treatment

Pre RTM Treatment Baseline qEEG

5 Days Post-RTM Treatment qEEG
Training Initiatives

• Since last year R&R has provided training for more than 150 service providers from VA Centers and private organizations.

• A review of those trainees’ work with RTM finds that they are able to replicate the results of our studies after a brief 4-day training.

• We are developing contracts for training 1000 more providers in the next two years.

• Evaluations of all trainings to date rate the training and the clinical effectiveness of the RTM protocol at 9.5 or above (10 point scale).
Pending Research

• We are proud to announce that we have begun a two-year research study funded by the Center for Neuroscience and Regenerative medicine (CNRM) at the Uniformed Services University, Walter Reed National Military Medical Center, under the Leadership of Dr. Michael Roy, MD, PhD.

• King's College London, fund by the Governments, Forces in Mind Trust (FiMT), has begun a randomized control trial of RTM for ex-Service personnel with PTSD at three clinics in Belfast Northern Ireland.
Selected References


Transforming traumatic memories: The Reconsolidation of Traumatic Memories (RTM) protocol

The Research and Recognition Project
(a 501(c)(3) organization)

Frank Bourke, CEO
Frank.Bourke@randrproject.com